BCAB News and Press, BioAtla Inc. From 10/10/23

2023-10-10 18:08:38 ET Gainers: VOXX International  ( VOXX ) +10% . BioAtla ( BCAB ) +6% . Poseida Therapeutics ( PSTX ) +5% . Diversified Healthcare  ( DHC ) +5% . Alignment Healthcare ( ALHC ) +4% . Losers: Si...

Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned for December 4, 2023, following conclusion of the IASLC conference R&D day planned for December 13, 2023, to discuss BA30...

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management...

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management ...

2023-08-01 23:18:02 ET BioAtla, Inc. (BCAB) Q2 2023 Earnings Conference Call August 1, 2023 16:30 ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman & Chief Medical Officer Richard Waldron - Chief Financial Officer Eric ...

2023-08-01 17:07:19 ET BioAtla press release ( NASDAQ: BCAB ): Q2 Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the same quarter in 2022. Net cash used in operating activiti...

Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug Administration (FDA) meeting request for potentially registrational study of BA3011 in non-smal...

SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference ca...

2023-06-26 13:31:32 ET BioAtla ( NASDAQ: BCAB ) said Monday it has been added as a member of the U.S. small-cap Russell 2000 Index as part of the 2023 Russell indexes reconstitution. Press Release . For further details see: BioAtla joins Russe...

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company has been added as a ...